Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
BACKGROUND
This report describes the use of combined laser photocoagulation and intravitreal bevacizumab administration for aggressive zone I retinopathy of prematurity (ROP).


METHODS
A male patient, born at 25 weeks gestation with a birth weight of 884 g, received indirect laser photocoagulation and a 0.75 mg intravitreal bevacizumab injection to each eye for aggressive stage 3 zone I ROP. Structural outcomes were evaluated 3 months after treatment.


RESULTS
At 3-month follow-up, treatment had resulted in ROP regression, prompt resolution of plus signs and neovascular proliferation in both eyes, and no signs of systemic or ocular adverse events.


CONCLUSIONS
The combination of indirect laser photocoagulation and intravitreal bevacizumab injection was well tolerated and induced prompt regression of aggressive zone I ROP.
Chung
Eun Jee
EJ
The Institute of Vision Research, Department of Ophthalmology,Yonsei University College of Medicine, Seoul, South Korea.
Kim
Ji Hyun
JH
Ahn
Hyun Seok
HS
Koh
Hyoung Jun
HJ
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D005865:Gestational Age; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007267:Injections; D017075:Laser Coagulation; D008297:Male; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000601:surgery*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
J AAPOS. 1999 Feb;3(1):26-32
10071898
Arch Ophthalmol. 2000 May;118(5):645-9
10815156
N Engl J Med. 1994 Dec 1;331(22):1480-7
7526212
Arch Ophthalmol. 1996 Oct;114(10 ):1219-28
8859081
Retina. 2006 Sep;26(7 Suppl):S11-5
16946670
Am J Ophthalmol. 2006 Jul;142(1):162-4
16815270
Lab Invest. 1996 Jan;74(1):68-77
8569199
Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):905-9
7846076
Clin Exp Ophthalmol. 2000 Feb;28(1):48-52
11345346
J AAPOS. 2000 Dec;4(6):373-6
11124674
Indian J Ophthalmol. 2007 Jan-Feb;55(1):75-6
17189897
Retina. 2006 Mar;26(3):262-9
16508424
Ann Pharmacother. 2007 Apr;41(4):614-25
17355998
Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):233-7
17552391
Retina. 2006 Oct;26(8):871-6
17031285
J Neurosci. 2000 Sep 15;20(18):6781-8
10995821
Am J Pathol. 1997 Jul;151(1):281-91
9212753
Arch Ophthalmol. 2003 Dec;121(12 ):1684-94
14662586
Br J Ophthalmol. 2006 Nov;90(11):1344-9
16854824
Acta Ophthalmol Scand. 2003 Dec;81(6):614-6
14641264
Arch Ophthalmol. 1990 Feb;108(2):195-204
2405827
Ophthalmology. 2006 Oct;113(10):1695.e1-15
17011951
Retina. 2006 Mar;26(3):257-61
16508423
Am J Ophthalmol. 2006 Jul;142(1):46-59
16815250